Literature DB >> 19023550

The effects of ketorolac tromethamine and baicalein on the levels of inflammatory factors in human synoviocytes.

Jae-Heon Yang1, Mi-Young Yun, Nam-Hee Lee, Dae-Keun Kim, Young-Il Kim, Young-Hee Noh, Tae-Youl Kim, Se-Won Yoon, Sang-Chul Shin.   

Abstract

This study examined the effects of ketorolac tromethamine (KT) and baicalein (BE) on the levels of inflammatory factors in human synoviocytes. The fibroblast-like synoviocytes (FLS) cells were used to determine the possible regulatory effects of KT and BE (KTBE) on the levels of inflammatory factors in FLS cells. In addition, the levels of TNF-alpha, IL-6, and IL-1beta mRNA expression in FLS cells induced by a TNF-alpha and IL-1beta co-treatment were largely inhibited by a KTBE treatment. The level of FLS cells proliferation was increased by IL-1beta and TNF-alpha, and strongly inhibited by KTBE treatment. The production of oxygen species (ROS) was inhibited by KTBE in FLS cells. KTBE appears to regulate the levels of mRNA that are important for regulating RA progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023550     DOI: 10.1007/s12272-001-2138-6

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  3 in total

1.  Baicalein inhibits interleukin-1β-induced proliferation of human rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  Shuo Chen; Yang Yang; Hui Feng; Hehong Wang; Riguang Zhao; Hongbin Liu
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

2.  The role of intestinal microflora in anti-inflammatory effect of baicalin in mice.

Authors:  Myung-Ah Jung; Se-Eun Jang; Sung-Woon Hong; Myung Joo Hana; Dong-Hyun Kim
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

3.  Baicalein Induces Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts through Inactivation of the PI3K/Akt/mTOR Pathway.

Authors:  Xue Zhang; Xia Guan; Yingshi Piao; Xiangguo Che; Mengge Si; Jingchun Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-07       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.